## House Bill 759 (AS PASSED HOUSE AND SENATE)

By: Representatives Parrish of the 158<sup>th</sup>, Stephens of the 164<sup>th</sup>, Fleming of the 121<sup>st</sup>, Welch of the 110<sup>th</sup>, and Burns of the 159<sup>th</sup>

## A BILL TO BE ENTITLED AN ACT

To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to
controlled substances, so as to change certain provisions relating to Schedule IV controlled
substances; to change certain provisions relating to the definition of dangerous drug; to
provide for an effective date; to repeal conflicting laws; and for other purposes.
BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:
SECTION 1.
Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled
substances, is amended by revising subsection (a) of Code Section 16-13-28, relating to
Schedule IV controlled substances, by adding a new paragraph to read as follows:
"(30.25) Solriamfetol, including its salts, isomers, and salts of isomers;"
SECTION 2.
SECTION 2. Said chapter is further amended by revising subsection (b) of Code Section 16-13-71, relating
Said chapter is further amended by revising subsection (b) of Code Section 16-13-71, relating
Said chapter is further amended by revising subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, by adding new paragraphs to read as follows:
Said chapter is further amended by revising subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, by adding new paragraphs to read as follows: "(17.05) Afamelanotide:"
Said chapter is further amended by revising subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, by adding new paragraphs to read as follows: "(17.05) Afamelanotide;" "(17.4) Air polymer-type A;"
Said chapter is further amended by revising subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, by adding new paragraphs to read as follows: "(17.05) Afamelanotide;" "(17.4) Air polymer-type A;" "(22.7) Alpelisib;"
Said chapter is further amended by revising subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, by adding new paragraphs to read as follows: "(17.05) Afamelanotide;" "(17.4) Air polymer-type A;" "(22.7) Alpelisib;" "(106.3) Bremelanotide;"
Said chapter is further amended by revising subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, by adding new paragraphs to read as follows: "(17.05) Afamelanotide;" "(17.4) Air polymer-type A;" "(22.7) Alpelisib;" "(106.3) Bremelanotide;" "(107.1) Brexanolone;"
Said chapter is further amended by revising subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, by adding new paragraphs to read as follows: "(17.05) Afamelanotide;" "(17.4) Air polymer-type A;" "(22.7) Alpelisib;" "(106.3) Bremelanotide;" "(107.1) Brexanolone;" "(107.45) Brilliant blue G ophthalmic solution;"
Said chapter is further amended by revising subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, by adding new paragraphs to read as follows: "(17.05) Afamelanotide;" "(17.4) Air polymer-type A;" "(22.7) Alpelisib;" "(106.3) Bremelanotide;" "(107.1) Brexanolone;" "(107.45) Brilliant blue G ophthalmic solution;" "(107.7) Brolucizumab-dbll;"
Said chapter is further amended by revising subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, by adding new paragraphs to read as follows: "(17.05) Afamelanotide:" "(17.4) Air polymer-type A:" "(22.7) Alpelisib:" "(106.3) Bremelanotide:" "(107.1) Brexanolone:" "(107.45) Brilliant blue G ophthalmic solution:" "(107.7) Brolucizumab-dbll;" "(132.7) Caplacizumab-yhdp:"
Said chapter is further amended by revising subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, by adding new paragraphs to read as follows:    "(17.05) Afamelanotide;"   "(17.4) Air polymer-type A:"   "(22.7) Alpelisib;"   "(106.3) Bremelanotide;"   "(107.1) Brexanolone;"   "(107.45) Brilliant blue G ophthalmic solution:"   "(107.7) Brolucizumab-dbll;"   "(132.7) Caplacizumab-yhdp:"   "(151.55) Cefiderocol;"

20

26	"(331.054) Elexacaftor;"
27	"(332.1) Enfortumab vedotin-ejfv;"
28	"(332.86) Entrectinib;"
29	"(334.91) Erdafitinib;"
30	"( <u>381.25</u> ) Fedratinib;"
31	"(383.2) Ferric maltol;"
32	"(396.3) Fluorodopa F 18;"
33	"(408.1) Ga-68-DOTATOC;"
34	"(415.01) Givosiran;"
35	"(424.6) Golodirsen;"
36	"(506.6) Istradefylline;"
37	"(512.691) Lasmiditan;"
38	"(513.4) Lefamulin;"
39	"(531.45) Lumateperone tosylate;"
40	"(531.75) Luspatercept-aamt;"
41	"(706.7) Pexidartinib;"
42	"(740.7) Pitolisant;"
43	"(746.5) Polatuzumab vedotin-piiq;"
44	"(768.5) PrabotulinumtoxinA-xvfs;"
45	"(772.5) Pretomanid;"
46	"(832.9) Relebactam;"
47	"(843.15) Risankizumab-rzaa;"
48	"(845.2) Romosozumab-aqqg;"
49	"(853.8) Selinexor;"
50	"(858.4) Siponimod;"
51	"(930.901) Tafamidis meglumine;"
52	"(931.79) Tenapanor;"
53	"(974.2) Trastuzumab;"
54	"(981.5) Triclabendazole;"
55	"(985.5) Trifarotene;"
56	"(1018.3) Ubrogepant;"
57	"(1019.7) Upadacitinib;"
58	"(1037.85) Voxelotor;"
-	

59 "(1042.04) Zanubrutinib;"

	20 LC 33 8116/AP
60	SECTION 3.
61	Said chapter is further amended in Code Section 16-13-71, relating to the definition of
62	dangerous drug, by revising paragraph (361.5) of subsection (b) to read as follows:
63	"(361.5) Ethinamate Reserved;"
64	<b>SECTION 4.</b>
65	Said chapter is further amended in Code Section 16-13-71, relating to the definition of
66	dangerous drug, by revising paragraph (529.93) of subsection (b) to read as follows:
67	"(529.93) Lorcaserin hydrochloride Reserved;"
68	SECTION 5.
69	This Act shall become effective upon its approval by the Governor or upon its becoming law
70	without such approval.
71	SECTION 6.

72 All laws and parts of laws in conflict with this Act are repealed.